ArticleNature chemical biology2019
Targeted delivery of nitric oxide via a 'bump-and-hole'-based enzyme-prodrug pair.
Article in Nature chemical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Harnessing gasotransmitters for orthopaedic infection therapy: Mechanisms and advanced delivery platforms.Bioactive materials · 2027Review
- Design rules for bioorthogonal glycan-based tools.The Biochemical journal · 2026Review
- Nanomachines Based on Inner Ultrasonic Multiple Scattering for Ameliorating Renal Function.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- A Radioresistant-Tumor-Targeted Nanoparticle for X-Ray-Controlled Nitric Oxide Release to Potentiate Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Mechanical mechanics-reclaiming a new battlefield for chronic liver disease.Journal of advanced research · 2026Review
- Ascorbate elastomer-coated ePTFE grafts inhibit neointimal hyperplasia and enhance vascular healing.Bioactive materials · 2026Article
- Precise Delivery of Nitric Oxide Controlled by Bioorthogonal Endocellulase Ameliorates Hindlimb Ischemia.Bioengineering (Basel, Switzerland) · 2026Article
- Determinants of graft patency after coronary artery bypass grafting.Frontiers in cardiovascular medicine · 2026Review
- Advances in Surface Biofunctionalization and Intelligent Monitoring of Vascular Scaffolds.Research (Washington, D.C.) · 2026Review
- Enhanced nanoparticle delivery across vascular basement membranes of tumours using nitric oxide.Nature biomedical engineering · 2025Article
- Radiotherapy-Activated Prodrug: Past, Present and Beyond.ACS central science · 2025Review
- Delivery of Molecular Hydrogen for Precision Immunomodulation: Mechanisms, Detection Methods, and Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Morpholine-Facilitated Enrichment-Triggered Delivery of Carbon Monoxide to Lysosome: A Feasibility Study.Chemical biology & drug design · 2025Article
- Targeted codelivery of nitric oxide and hydrogen sulfide for enhanced antithrombosis efficacy.Bioactive materials · 2025Article
- Tandem activated caged galactoside prodrugs: advancing beyond single galactosidase dependence.Chemical science · 2025Article
- Induction of Nitric Oxide and Its Role in Otitis Media.Antioxidants (Basel, Switzerland) · 2025Review
- Emerging strategies for nitric oxide production and their topical application as nanodressings to promote diabetic wound healing.Journal of nanobiotechnology · 2025Review
- Exosomes in arteriovenous fistula stenosis.Frontiers in cell and developmental biology · 2025Review
- Fenoldopam for Renal Protection in Cardiac Surgery: Pharmacology, Clinical Applications, and Evolving Perspectives.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spatiotemporal generation of nitric oxide (NO), a versatile endogenous messenger, is precisely controlled. Despite its therapeutic potential for a wide range of diseases, NO-based therapies are limited clinically due to a lack of effective strategies for precisely delivering NO to a specific site. In the present study, we developed a novel NO delivery system via modification of an enzyme-prodrug pair of galactosidase-galactosyl-NONOate using a 'bump-and-hole' strategy. Precise delivery to targeted tissues was clearly demonstrated by an in vivo near-infrared imaging assay. The therapeutic potential was evaluated in both rat hindlimb ischemia and mouse acute kidney injury models. Targeted delivery of NO clearly enhanced its therapeutic efficacy in tissue repair and function recovery and abolished side effects due to the systemic release of NO. The developed protocol holds broad applicability in the targeted delivery of important gaseous signaling molecules and offers a potent tool for the investigation of relevant molecular mechanisms.
Indexed as
Identifiers
30598545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.